MAGEA3 (melanoma antigen family A, 3)

2014-04-01   Biswajit Das , Sujit Suklabaidya , Sumeet Jain , Manas R Baisakh , Shantibhusan Senapati 

Institute of Life Sciences, Bhubaneswar, Odisha 751023, India (BD, SSu, SJ, SSe); Apollo Hospital, Bhubaneswar, Odisha 751003, India (MRB)

Identity

HGNC
LOCATION
Xq28
LOCUSID
ALIAS
CT1.3,HIP8,HYPD,MAGE3,MAGEA6

Abstract

In the year 1991 Van der Bruggen P et al. cloned and named MAGE-1 gene that encodes MZ2E antigen, which is expressed in melanoma tissues and cell lines (van der Bruggen et al., 1991). Since then based on sequence similarity MAGE family has expanded to more than 60 genes (Chomez et al., 2001). According to their chromosomal location and tissue-specific expression pattern, all the members of this family are categorized into two groups; type I (cancer and testis specific) and type II (ubiquitous) MAGE. MAGEA sub-family has 12 members starting from MAGEA1 to MAGEA12, among them MAGEA7 is a pseudo-gene (Doyle et al., 2010). The current review summarizes the information specifically on MAGEA3s DNA\/RNA, protein structure, function and where the gene is implicated.

DNA/RNA

Description

In human X chromosome; MAGEA3, is clustered in q28 along with other MAGEA sub-family members. The gene consists of three exons and is distributed over 3588 bp (Figure 1).

Transcription

MAGEA3 gets transcribed from the reverse (minus/negative) strand of the DNA. The transcript or m-RNA harbors three exons, but only the 3rd exon contributes to the whole ORF (Figure 1). Three transcript variants have been reported till date.

Proteins

Atlas Image
Figure 1. Genomic organization and protein domain structure of MAGEA3.

Description

The MAGEA3 protein consists of 314 amino acids. The protein has a molecular weight of 34747 Da and pI 4.57. Like other MAGEA family members, it has a conserved MAGE homology domain (MHD; 116 aa - 286 aa) (Sang et al., 2011). Unfortunately, till date no clear functional role has been identified for this domain. The protein has also one MAGE NH2-terminal and one MAGE COOH-terminal region in its structure (Figure 1). The MAGEA3 protein is 85% and 95% identical to MAGEA2 and MAGEA6, respectively (Atanackovic et al., 2010).

Expression

The expression of MAGEA3 is restricted to germ cells of testis (primary spermatocytes and spermatogonia) and placental trophoblast, but no other somatic cellular expression have been reported except in wide variety of tumor cells.

Localisation

Cytoplasmic and nuclear expression has been reported (Atanackovic et al., 2010; Barker and Salehi, 2002; Guo et al., 2013).

Function

Since the MAGA3 protein is restricted to germ cell of testis and trophoblast of placenta which are immune privileged tissues, the protein is highly immunogenic and recognized by CTLs when expressed elsewhere. Its role in spermatogenesis and embryo development is still unknown. A report says MAGEA3 has the ability to repress p53 function/transactivation, and MAGEA3 knockdown results in increased accumulation of p53 target genes in response to DNA damage (Monte et al., 2006). Moreover, MAGEA3 directly interacts with and enhances the ubiquitin ligase activity of TRIM28 (a RING E3 ubiquitin ligase) and has a probable role in p53 degradation (Doyle et al., 2010). Its other functional implications in various cancer cells are mentioned in this report. MAGEA family members have significant protein sequence identity, which suggests a functional similarity among them. However, a distinct variability in the regulatory regions of MAGEA genes suggests a possible molecular mechanism of carrying out the same function by different members, under different transcription control.

Regulation
Till now demethylation of promoter region has been reported as the major regulatory mechanism that leads to unusual derepression of MAGEA3 in cancer cells (Figure 2). Histone acetylation is also reported to regulate the expression of MAGEA3 in cancer cells (Kim et al., 2006b; Wischnewski et al., 2006).The MAGEA3 promoter is found to be hypermethylated in response to FGFR2-IIIb and/or FGF7 stimulating signals resulting into MAGEA3 silencing in MAGEA3-positive thyroid cancer cell lines (Kondo et al., 2007). MBD1, a methyl-CpG Binding Domain protein is reported to have the ability to bind the unmethylated promoter of MAGEA3 and suppresses the promoter activity that cannot be retracted by Ets-1 transcription factor (Wischnewski et al., 2007).

Atlas Image
Figure 2. Role of MAGEA3-promoter methylation in spatiotemporal regulation of MAGEA3 gene expression.

Homology

Around eight different organisms have orthologs with human MAGEA3.

Implicated in

Entity name
Various cancers
Note
MAGEA3 expression is being reported in colorectal cancer, breast cancer (10%), bladder cancer (37%), pancreatic cancer (40%), multiple myeloma (41%), gastric cancer (48%), glioma (51.3%), melanoma (65%), thyroid cancer (65%) and NSCLC (85%). Information about MAGEA3 expression and significance in various malignancies is mentioned below.
Entity name
Pancreatic ductal adenocarcinoma
Note
MAGEA3 expression has been reported in pancreatic cancer cell lines and tissues. Its expression significantly correlates with poor prognosis in pancreatic cancer patients (Cogdill et al., 2012; Kim et al., 2006a; Kubuschok et al., 2004).
Entity name
Colorectal cancer
Note
Colorectal cancer cell lines express MAGEA3 and its expression in tumor tissue samples significantly correlates with tumor size (Kim et al., 2006b; Shantha Kumara et al., 2012).
Entity name
Note
MAGEA3 expression has been detected in multiple myeloma cell lines and patients samples. Its expression correlates with disease progression i.e. the frequency of expression is higher in relapsed patients than newly diagnosed individuals. Further, silencing of MAGEA3 induced intrinsic apoptosis pathway in proliferating multiple myeloma cells, which indicates the functional role of MAGEA3 in inhibiting apoptosis of cancer cells (Atanackovic et al., 2010; Nardiello et al., 2011).
Entity name
Thyroid carcinoma
Note
MAGEA3 expression has been detected in patient tissue samples and its expression was high in the small papillary carcinoma. Experimental evidences suggest a possible functional role of MAGEA3 in thyroid carcinoma cells growth, invasion and metastasis (Liu et al., 2008).
Entity name
Breast cancer
Note
MAGEA3 mRNA expression has been reported in breast cancer patient tissue samples. Detection of MAGEA3 mRNA in the sentinel lymph nodes (SLN) of breast cancer patients indicates a high chance of micro-metastasis. It is mostly expressed in the intermediate or poorly differentiated primary breast carcinoma, which is associated with poor prognosis and contributes to higher recurrence rate (Otte et al., 2001; Wascher et al., 2001).
Entity name
Lung cancer (NSCLC)
Note
MAGEA3 mRNA expression has been reported in lung cancer patient tissue samples. High level of MAGEA3 is a potential marker for poor prognosis in NSCLC patients (Gure et al., 2005).
Entity name
Non-Hodgkins lymphoma
Note
MAGEA3 expression has been detected both in cell lines and tissue samples (at RNA level). MAGEA3 in peripheral blood of patients can be a potential tumor marker and is a therapeutic target (Han et al., 2010).
Entity name
Leukemia
Note
High level of MAGEA3 expression significantly correlates with higher bone marrow blast (Martínez et al., 2007).
Entity name
Glioma
Note
MAGE3 protein has been detected in glioma tissue samples. Its expression level does not reflect significant difference in overall survival of patients between the pathological grades (Guo et al., 2013).
Entity name
Gastric cancer
Note
Gastric cancer cell lines express MAGEA3; however, no functional data has been reported till date (Honda et al., 2004).

Bibliography

Pubmed IDLast YearTitleAuthors
200158852010Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.Atanackovic D et al
118917832002The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease.Barker PA et al
114547052001An overview of the MAGE gene family with the identification of all human members of the family.Chomez P et al
227708032012Targeting the MAGE A3 antigen in pancreatic cancer.Cogdill AP et al
208640412010MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.Doyle JM et al
239467772013The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma.Guo L et al
162992362005Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.Gure AO et al
200364222010Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood.Han MH et al
149708622004Demethylation of MAGE promoters during gastric cancer progression.Honda T et al
163316182006The clinical significance of MAGEA3 expression in pancreatic cancer.Kim J et al
170070172006Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.Kim KH et al
176998482007The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.Kondo T et al
149915792004Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis.Kubuschok B et al
188295692008The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis.Liu W et al
168064672007mRNA expression of MAGE-A3 gene in leukemia cells.Martínez A et al
168472672006MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.Monte M et al
215659822011MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.Nardiello T et al
115595352001MAGE-A gene expression pattern in primary breast cancer.Otte M et al
219336942011MAGE-A family: attractive targets for cancer immunotherapy.Sang M et al
233903712012MAGE-A3 is highly expressed in a subset of colorectal cancer patients.Shantha Kumara HM et al
117204722001Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes.Wascher RA et al
176344282007Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.Wischnewski F et al
18407031991A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.van der Bruggen P et al

Other Information

Locus ID:

NCBI: 4102
MIM: 300174
HGNC: 6801
Ensembl: ENSG00000221867

Variants:

dbSNP: 4102
ClinVar: 4102
TCGA: ENSG00000221867
COSMIC: MAGEA3

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000221867ENST00000370278P43357
ENSG00000221867ENST00000417212E7EMU0
ENSG00000221867ENST00000598245P43357

Expression (GTEx)

0
5
10
15

References

Pubmed IDYearTitleCitations
256797632015Degradation of AMPK by a cancer-specific ubiquitin ligase.99
188295692008The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis.53
182371052008Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.49
200158852010Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.36
288096082017Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.32
215659822011MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.26
197951702009Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.25
229259302012Analysis of the processing of seven human tumor antigens by intermediate proteasomes.24
237283522013Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.24
123936752003Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.23

Citation

Biswajit Das ; Sujit Suklabaidya ; Sumeet Jain ; Manas R Baisakh ; Shantibhusan Senapati

MAGEA3 (melanoma antigen family A, 3)

Atlas Genet Cytogenet Oncol Haematol. 2014-04-01

Online version: http://atlasgeneticsoncology.org/gene/41247/magea3